When AI Meets FDA: Credibility Over Capability in Pharma

Artificial Intelligence is becoming increasingly important across the pharmaceutical industry, influencing clinical trials, manufacturing, pharmacovigilance, and regulatory submissions. In this episode of The GMP Insider, we explore the FDA's emerging expectations for AI in regulatory decision-making and why credibility matters more than capability. The FDA's latest guidance introduces a risk-based credibility framework, emphasizing that AI models must be validated within a clearly defined Context of Use (COU). The focus is no longer just on performance — it is on reliability, transparency, reproducibility, and explainability. Discussion topics include:• FDA expectations for AI-supported decisions• The role of Context of Use in validation• Why higher-risk decisions require stronger evidence• Challenges with “black box” AI models• The future of AI governance in regulated environments As AI becomes more integrated into pharmaceutical systems, Quality professionals must ensure that innovation is supported by strong validation, oversight, and accountability. In pharma, credibility is what earns regulatory trust.